

Data Sharing Statement

Woyach JA, Ruppert AS, Heerema NA, et al. Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. N Engl J Med. DOI: 10.1056/NEJMoa1812836.

Question	Authors' Response
Will the data collected for your study be made available to others?	Yes, via the NCTN data archive
Would you like to offer context for your decision?	Data will be made available per policies of the Alliance for Clinical Trials in Oncology
Which data?	—
Additional information about data	—
How or where can the data be obtained?	—
When will data availability begin?	—
When will data availability end?	—
Will any supporting documents be available?	—
Which supporting documents?	—
Additional information about supporting documents	—
How or where can supporting documents be obtained?	—
When will supporting documents availability begin?	—
When will supporting documents availability end?	—
To whom will data be available?	—
For what type of analysis or purpose?	—
By what mechanism?	—
Any other restrictions?	—
Additional information	—

This statement was posted on December 1, 2018, at NEJM.org.